Innovus Pharmaceuticals (Innovus Pharmaceuticals) Forward Dividend Yield % : 0.00% (As of Apr. 28, 2024)

View and export this data going back to 2008. Start your Free Trial

What is Innovus Pharmaceuticals Forward Dividend Yield %?

As of today (2024-04-28), the Forward Annual Dividend Yield of Innovus Pharmaceuticals is 0.00%.

As of today (2024-04-28), the Trailing Annual Dividend Yield of Innovus Pharmaceuticals is 0.00%.

INNV's Forward Dividend Yield % is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 1.89
* Ranked among companies with meaningful Forward Dividend Yield % only.

Innovus Pharmaceuticals's Dividends per Share for the three months ended in Sep. 2019 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Innovus Pharmaceuticals's Forward Dividend Yield %

For the Drug Manufacturers - Specialty & Generic subindustry, Innovus Pharmaceuticals's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Innovus Pharmaceuticals's Forward Dividend Yield % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Innovus Pharmaceuticals's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Innovus Pharmaceuticals's Forward Dividend Yield % falls into.

Innovus Pharmaceuticals Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

Innovus Pharmaceuticals (OTCPK:INNV) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Innovus Pharmaceuticals Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Innovus Pharmaceuticals's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Innovus Pharmaceuticals (Innovus Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Innovus Pharmaceuticals Inc (OTCPK:INNV) » Definitions » Forward Dividend Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

8845 Rehco Road, San Diego, CA, USA, 92121

Website

http://www.innovuspharma.com

Innovus Pharmaceuticals Inc is engaged in the healthcare industry. It is a specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men's and women's health and vitality and respiratory diseases. Innovus distributes OTC medicines and consumer and health products directly, through commercial partners to primary care physicians, urologists, gynecologists and therapists, and directly to consumers through its on-line channels, retailers, and wholesalers.

Executives

Armistice Capital, Llc	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital Master Fund Ltd.	10 percent owner	C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Vivian H Liu	director
Henry Jemil Esber	director	38 ANGELL BROOK DRIVE, WEST BOYLSTON MA 01853
Randy Berholtz	officer: EVP, CORPORATE DEVELOPMENT	6330 NANCY RIDGE DRIVE, SUITE 103, SAN DIEGO CA 92121
Ryan J Selhorn	officer: VP, CFO	4275 EXECUTIVE SQUARE, SUITE 650, LA JOLLA CA 92037
Bassam Damaj	director, officer: CHIEF EXECUTIVE OFFICER	C/O BIO-QUANT, INC., 6330 NANCY RIDGE DRIVE, SUITE 103, SAN DIEGO CA 92121
Robert Hoffman	officer: Chief Financial Officer	ARENA PHARMACEUTICALS INC, 6166 NANCY RIDER DRIVE, SAN DIEGO CA 92121
Morgan R Brown	officer: See remarks	420 CHIPETA WAY, SALT LAKE CITY UT 84108
Jacki Bartholomew	director	175 SOUTH MAIN STREET, NO 1212, SALT LAKE CITY UT 84111
Thomas L Harkness	director, officer: Secretary	175 SOUTH MAIN STREET, NO 1212, SALT LAKE CITY UT 84111
Wallace Boyack	director, 10 percent owner, officer: President & CEO	175 S MAIN ST, NO 1212, SALT LAKE CITY UT 84111